Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
GlobalData reports 320% rise in pharma M&A deal value in September 2025
Pharma industry recorded $20.5 billion in M&A deals and $2.8 billion in venture capital funding during September 2025,…
Sai Life Sciences, Agility Life Sciences and Centrix Pharma Solutions launch integrated CMC…
The collaboration offers end-to-end Chemistry, Manufacturing and Controls (CMC) services to support biopharma innovators from…
Parexel expands site alliance program to accelerate study start-up and patient enrolment
Enhanced program delivers 40% faster site activation, 20% faster study start-up timelines and four times more patient enrolments…
General Atlantic Singapore transfers 3.49 million Rubicon Research shares ahead of IPO
Shares worth Rs 169 crore transferred to mutual funds, while Rubicon Research opens IPO from 9–13 October 2025
Shanchol oral cholera vaccine receives WHO prequalification
WHO prequalification enables global agencies including UNICEF, Gavi, and PAHO to procure Shanchol for countries facing cholera…
DIA announces virtual attendance option for MedTech Conclave 2025
The Drug Information Association introduces a virtual format for the inaugural MedTech Conclave 2025 to facilitate wider…
ENTOD Pharmaceuticals launches OCUBIOME, India’s first ocular probiotic blend
New formulation targets eye health by restoring ocular and gut microbiota balance, supporting long-term wellness
HRV Pharma introduces brand mascots Max and Luna to represent company values
HRV Pharma unveils macaw-inspired mascots symbolising trust, loyalty, and long-term partnerships
uniQure’s gene therapy for Huntington’s disease holds blockbuster potential: GlobalData
GlobalData reports that uniQure’s AMT-130 shows disease-slowing potential in Huntington’s disease, though high costs, surgical…
Biomea Fusion reports blood sugar control with icovamenib in type 2 diabetes study
Mid-stage trial results show sustained blood sugar reduction and potential benefit for patients unresponsive to GLP-1 therapies